Evidence map›Paper›PMID 35340044›Full record

Trial reportClinical and experimental dermatology2022

Prescribing and using vitiligo treatments: lessons from a nested process evaluation within the HI-Light vitiligo randomized controlled trial.

Paul Leighton, Joanne R Chalmers, Jonathan M Batchelor, Andy Rogers, Perways Akram, Rachel H Haines, Garry D Meakin, Jennifer White, Jane C Ravenscroft, Tracey H Sach and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Paul LeightonCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-5208-0274
Joanne R ChalmersCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-2281-7367
Jonathan M BatchelorCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-7728-2021
Andy RogersDepartment of Medical Physics and Clinical Engineering, Nottingham University Hospitals NHS Trust, Nottingham, UK.ORCID https://orcid.org/0000-0003-4734-9528
Perways AkramDepartment of Medical Physics and Clinical Engineering, Nottingham University Hospitals NHS Trust, Nottingham, UK.ORCID https://orcid.org/0000-0002-2510-0345
Rachel H HainesNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-7924-0602
Garry D MeakinNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-8593-3421
Jennifer WhiteNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0003-1945-7644
Jane C RavenscroftDepartment of Paediatric Dermatology, Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK.ORCID https://orcid.org/0000-0002-1609-7084
Tracey H SachNorwich Medical School, University of East Anglia, Norwich, UK.ORCID https://orcid.org/0000-0002-8098-9220
Miriam SanterPrimary Care and Population Sciences, University of Southampton, Southampton, UK.ORCID https://orcid.org/0000-0001-7264-5260
Maxine E WhittonCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-9902-7809
Viktoria EleftheriadouWalsall Manor Hospital, Walsall, UK.ORCID https://orcid.org/0000-0001-5776-1466
Kim S ThomasCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-7785-7465
University of Nottingham · GBNottingham University Hospitals NHS Trust · GBUniversity of East Anglia · GBUniversity of Southampton · GBWalsall Manor Hospital · GB

Funding

Health Technology Assessment Programme HTA Project Reference 12/24/02
6 · The paper itself

Abstract

backgroundThe HI-Light Trial demonstrated that for active, limited vitiligo, combination treatment with potent topical corticosteroid (TCS) and handheld narrowband ultraviolet B offers a better treatment response than potent TCS alone. However, it is unclear how to implement these findings.

aimWe sought to answer three questions: (i) Can combination treatment be used safely and effectively by people with vitiligo?; (ii) Should combination treatment be made available as routine clinical care?; and (iii) Can combination treatment be integrated within current healthcare provision?

methodsThis was a mixed-methods process evaluation, including semi-structured interviews with a purposive sample of trial participants, structured interviews with commissioners, and an online survey and focus groups with trial staff. Transcripts were coded by framework analysis, with thematic development by multiple researchers.

resultsParticipants found individual treatments easy to use, but the combination treatment was complicated and required nurse support. Both participants and site investigators felt that combination treatment should be made available, although commissioners were less certain. There was support for the development of services offering combination treatment, although this might not be prioritized above treatment for other conditions. A 'mixed economy' model was suggested, involving patients purchasing their own devices, although concerns regarding the safe use of treatments mean that training, monitoring and ongoing support are essential. The need for medical physics support may mean that a regional service is more practical.

conclusionCombination treatment should be made available for people seeking treatment for vitiligo, but services require partnership with medical physics and ongoing training and support for patients.

Indexed as

Dermatologic AgentsUltraviolet TherapyVitiligoHumansSurveys and QuestionnairesTreatment OutcomeDermatologic Agents

Identifiers

PMID35340044
PMCPMC9544377
OpenAlexW4221122935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.